RCS - Cambridge Cognition - Monument Therapeutics Success in Phase I Results

Cambridge Cognition HoldingsAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250624:nRSX0554Oa&default-theme=true

RNS Number : 0554O  Cambridge Cognition Holdings PLC  24 June 2025

 

24th June 2025

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Cambridge Cognition Investment, Monument Therapeutics, Achieves Positive Phase
I Results for Novel Schizophrenia Treatment

Cambridge Cognition (AIM: COG), the brain health software group specialising
in digital health products that advance brain health research and treatment,
is pleased to report that Monument Therapeutics, in which the Group has a 20%
holding, has achieved positive topline results from its Phase I clinical trial
of MT1988, a novel treatment for cognitive impairment associated with
schizophrenia (CIAS).

The positive Phase I results, which demonstrated favourable safety and
tolerability profiles for MT1988, represent an important milestone in
addressing CIAS, which is a core aspect of schizophrenia that significantly
impacts patients' daily functioning yet remains without approved treatment
options. These results support the advancement of MT1988 into Phase II
clinical development, targeting CIAS and related conditions.

Cambridge Cognition's proprietary digital cognitive assessment technologies
were instrumental in the early development phases of understanding cognitive
endpoints in this therapeutic area, contributing to the foundation upon which
Monument Therapeutics has built its clinical programme.

Monument Therapeutics was originally established by Cambridge Cognition as an
independent precision neuroscience company to develop novel treatments for
cognitive disorders, and the Group retains both an equity stake and a royalty
structure in Monument Therapeutics that entitles it to future revenues arising
from commercialisation of MT1988 and other programmes.

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"We are delighted to see Monument Therapeutics achieve this significant
milestone with MT1988. These promising results validate Monument's innovative
approach to addressing the critical unmet need in CIAS and we remain hopeful
that our investment, as well as potential future royalties, will be
significantly value enhancing."

 

 

 

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Jackson Redley                  cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

About Monument Therapeutics

Monument Therapeutics applies a unique novel drug development strategy,
leveraging digital assessments of cognition to match patients with new
pharmaceutical treatments. Lead asset MT1988 targets the cognitive symptoms of
schizophrenia, which are extremely costly for society and profoundly impact
the affected individuals and their quality of life.

For more information, please visit www.monumenttx.com
(https://www.monumenttx.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGZVVFNGKZM